Impact of Sacubitril/Valsartan on the Treatment Effectiveness, Serum Sirtuin-4 and Beclin-1 Levels of Chronic Heart Failure Patients

Abstract

Abstract: Objective To analyze the efficacy of sacubitril/valsartan in patients with chronic heart failure and its effect on cardiac function, serum sirtuin-4 (Sirtuin-4) and Beclin-1 levels. Methods Sixty chronic heart failure patients treated from January 2019 to September 2021 in Inner Mongolia International Mongolian hospital were investigated. According to random number table, patients were divided into control group (n=30, benazepril group) and observation group (n=30, sacubitril/valsartan group). The levels of left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), serum sirtuin-4 and beclin-1 before and after treatment, the total effective rate, the number of hospitalizations, the average length of stay and the incidence of adverse reactions were compared between the two groups. Results The effective treatment rate in the observation group was higher than control group (P<0.05). Before treatment, the levels of LVEF, LVESV and LVEDV between the two groups were not significantly different (P>0.05), and after treatment, the levels of LVEF, LVESV and LVEDV in the two groups were higher than those before treatment, and the levels of LVEF, LVESV and LVEDV in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). Before treatment, serum Sirtuin-4 and Beclin-1 levels between groups were not significantly different (P>0.05); after treatment, serum Sirtuin-4 and Beclin-1 levels in the observation group were lower than control group (P<0.05). The number of hospitalizations and the average hospitalization days in the observation group were less than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Sacubitril/valsartan has a definite curative effect in the treatment of chronic heart failure. It can improve the heart function of patients, reduce the serum levels of Sirtuin-4 and Beclin-1, and reduce the number of hospitalizations and the average length of hospitalization in patients, which is safe and worthy of clinical application.

Key words: chronic heart failure, sacubitril/valsartan, Beclin-1, Sirtuin-4

CLC Number:

R541.6

GUAN Jing-zhi, WANG Fei-fei, DAI Wen-jun, YUAN Shao-fei, SHI Lei. Impact of Sacubitril/Valsartan on the Treatment Effectiveness, Serum Sirtuin-4 and Beclin-1 Levels of Chronic Heart Failure Patients[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(3): 184-188.

References

[1] 曹洁. 沙库巴曲缬沙坦口服治疗中老年慢性心力衰竭51例临床观察[J].山东医药,2021,61(6):75-77.
[2] 王宏娟,陶启乐.沙库巴曲缬沙坦联合美托洛尔对老年慢性心力衰竭患者心功能、血管内皮功能及神经内分泌因子的影响[J].中国老年学杂志,2021,41(23):5183-5187.
[3] 李娜,古丽孜热木·阿布都马那甫.比较沙库巴曲缬沙坦和缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能的影响[J].河北医学,2021,27(7):1223-1227.
[4] 张锦,王占新,李海.沙库巴曲缬沙坦钠片对射血分数降低慢性心力衰竭患者的疗效分析[J].北方药学,2020,17(11):64-65.
[5] 安军钰,李万鹏,黄晏.自噬介导的STEMI心肌缺血-再灌注损伤中PAR-2、Bcl-2、Beclin1的表达及其相关性[J].现代临床医学,2021, 47(3):169-172.
[6] 王华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[7] 姚丹,郑菊,庞翀,等.沙库巴曲缬沙坦对慢性射血分数降低的心力衰竭患者超声参数的影响[J].实用临床医药杂志,2021,25(7):81-88.
[8] 阳飞,王芳,尹涛源.沙库巴曲缬沙坦治疗慢性心力衰竭的疗效[J].安徽医学,2021,42(8):876-880.
[9] 郭丽芬,胡晓军,程丽丹,等.沙库巴曲缬沙坦钠片对慢性心力衰竭病人血清炎性因子及心肌损伤标志物的影响[J].中西医结合心脑血管病杂志,2021,19(16):2806-2809.
[10] 谭红梅. 沙库巴曲缬沙坦治疗慢性心力衰竭的疗效观察[J].中国现代药物应用,2021,15(6):116-118.
[11] 王云峰. 沙库巴曲缬沙坦对慢性心力衰竭患者心功能和血清学指标表达的影响[J].四川解剖学杂志,2021,29(1):181-182.
[12] 孙静,寇进,胡建库,等.沙库巴曲缬沙坦治疗慢性心力衰竭肺动脉高压的疗效及对患者血清sICAM-1、sCD40L的影响[J].海南医学, 2020,31(2):149-152.
[13] 鲁俊,袁小龙.沙库巴曲缬沙坦治疗慢性心力衰竭及其对血清学指标的影响[J].皖南医学院学报,2020,39(4):344-347.
[14] 夏勇,张建卿,王少霞,等.沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报,2020,41(1):113-118.
[15] 董萌. 沙库巴曲缬沙坦钠治疗老年慢性心力衰竭合并肾功能不全患者的临床观察[J].中国中西医结合急救杂志,2020,27(1):84-87.
[16] 普顺华,蒋兴玲,郑甲林,等.沙库巴曲缬沙坦联合曲美他嗪治疗慢性充血性心力衰竭临床疗效观察[J].重庆医学,2020,49(4):539-543.
[17] 孙涛,闫继锋.比索洛尔联合沙库巴曲缬沙坦在慢性心力衰竭中的应用[J].重庆医学,2020,49(4):610-613.
[18] 孙莹,顾永丽,孙增先.252例心力衰竭住院患者沙库巴曲缬沙坦的用药分析[J].中国药房,2020,31(22):2801-2805.
[19] 司金萍,陈艳伟,杨洁,等.急性失代偿心力衰竭患者早期应用沙库巴曲缬沙坦的有效性和安全性评估[J].中华心血管病杂志,2020, 48(6):477-483.
[20] 金子安,陈阳.沙库巴曲缬沙坦治疗射血分数下降的慢性心力衰竭合并肾功能不全的临床疗效研究[J].实用心脑肺血管病杂志,2020, 28(5):91-95.